Use of finasteride reduces the risk of a prostate cancer diagnosis, but does not significantly affect mortality rates after following men for 18 years, according to a study presented at the 2013 Genitourinary Cancers Symposium.
Anticoagulant use is associated with improved overall survival in men receiving docetaxel chemotherapy for treatment of mCRPC, according to research presented at the 2013 Genitourinary Cancers Symposium.
A urine-based assay “can markedly improve the accuracy” of detecting bladder cancer noninvasively, according to a case-controlled validation study reported during the 2013 Genitourinary Cancers Symposium.
No significant difference in overall survival was found between tivozanib and sorafenib in patients with advanced renal cell carcinoma, according to research presented at the 2013 Genitourinary Cancers Symposium.
Concurrent administration of sipuleucel-T and abiraterone acetate plus prednisone is comparable to sipuleucel-T alone in men with metastatic castration-resistant prostate cancer, according to research from the 2013 Genitourinary Cancers Symposium.
Serum androgens appear to be prognostic of overall survival among men with castration-resistant prostate cancer, according to research presented at the 2013 Genitourinary Cancers Symposium.
Radium-223 dichloride is associated with significant improvements in overall survival among patients with castration-resistant prostate cancer and bone metastases, according to research presented at the 2013 Genitourinary Cancers Symposium.
Use of corticosteroids during treatment with enzalutamide reduces survival and increases adverse events in men with mCRPC who previously underwent docetaxel therapy, according to research presented at the 2013 Genitourinary Cancers Symposium.
ARN-509 is safe and well tolerated in men with high-risk nonmetastatic castration-resistant prostate cancer, according to research presented at the 2013 Genitourinary Cancers Symposium.
Abiraterone acetate prolongs survival among patients with metastatic castration-resistant prostate cancer who have not undergone prior chemotherapy, according to research presented at the 2013 Genitourinary Cancers Symposium.
